FIGURE 4.

Visualizing in vivo tumor targeting of ⁸⁹Zr-oxine–labeled PSCA-CAR T cells. (A) Representative PET (left) and PET/CT (right) maximum-intensity projections at 0.5 and 162 h, respectively. NSG mice with PC3-PSCA tumors in right flank (arrow) were intravenously treated with ⁸⁹Zr-oxine PSCA-CAR T cells (top row), ⁸⁹Zr-oxine–labeled mock-transfected T cells (middle row), or ⁸⁹Zr-oxine alone (bottom row). (B) Antihuman CD3 (brown) immunostaining for T cells in tumors of labeled or unlabeled mock or PSCA-CAR T cells. (C) Axial section showing PET signal of ⁸⁹Zr-oxine PSCA-CAR T cells at subcutaneous tumor (arrow) of representative mouse at 162 h. (D) Quantification of PET images in subcutaneous tumors of mice treated with ⁸⁹Zr-oxine PSCA-CAR T cells over 7 d.